These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8952778)

  • 41. Surfactant sufficiency for immature infants--prenatal induction vs. postnatal treatment.
    Taeusch HW; Smith BT
    Eur J Respir Dis Suppl; 1987; 153():249-54. PubMed ID: 3480820
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antenatal corticosteroids and respiratory distress syndrome - the first Polish national survey.
    Borszewska-Kornacka MK; Gulczyńska E; Kostuch M; Korbal P; Krajewski P; Study Group AT
    Ginekol Pol; 2016; 87(7):498-503. PubMed ID: 27504942
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Glucocorticoids and the respiratory distress syndrome in the newborn. A review of the literature].
    Gandibleux-Bergiers MF
    J Gynecol Obstet Biol Reprod (Paris); 1982; 11(5):625-37. PubMed ID: 6757311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of single and multiple courses of antenatal glucocorticoids in preterm newborns less than 30 weeks' gestation.
    Smith LM; Qureshi N; Chao CR
    J Matern Fetal Med; 2000; 9(2):131-5. PubMed ID: 10902829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucocorticoids and lung development in the fetus and preterm infant.
    Bolt RJ; van Weissenbruch MM; Lafeber HN; Delemarre-van de Waal HA
    Pediatr Pulmonol; 2001 Jul; 32(1):76-91. PubMed ID: 11416880
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Changes in fetal lung maturity after maternal treatment with glucocorticoids].
    Gherzi R; Cottafavi M
    Minerva Ginecol; 1979 Nov; 31(11):815-20. PubMed ID: 263702
    [No Abstract]   [Full Text] [Related]  

  • 47. New approaches to hormonal acceleration of fetal lung maturation.
    Schellenberg JC; Liggins GC
    J Perinat Med; 1987; 15(5):447-52. PubMed ID: 3327938
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of antenatal dexamethasone administration on respiratory distress syndrome in surfactant-treated infants.
    Farrell EE; Silver RK; Kimberlin LV; Wolf ES; Dusik JM
    Am J Obstet Gynecol; 1989 Sep; 161(3):628-33. PubMed ID: 2675599
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants.
    Liggins GC; Howie RN
    Pediatrics; 1972 Oct; 50(4):515-25. PubMed ID: 4561295
    [No Abstract]   [Full Text] [Related]  

  • 50. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants.
    Soll RF; Morley CJ
    Cochrane Database Syst Rev; 2001; (2):CD000510. PubMed ID: 11405966
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Artificial fetal lung maturation--prevention of antenatal complications in premature deliveries.
    Gojnic M; Pervulov M
    Clin Exp Obstet Gynecol; 2005; 32(1):61-4. PubMed ID: 15864942
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Avoiding the prenatal programming effects of glucocorticoids: are there alternative treatments for the induction of antenatal lung maturation?
    Justus G; Sloboda DM; Henrich W; Plagemann A; Dudenhausen JW; Braun T
    J Perinat Med; 2015 Sep; 43(5):503-23. PubMed ID: 25405717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antepartum prevention of respiratory distress syndrome (hyaline membrane disease).
    Sahu S
    J Iowa Med Soc; 1976 Dec; 66(12):481-3, 485-6. PubMed ID: 1036747
    [No Abstract]   [Full Text] [Related]  

  • 54. [Critical study of the use of glucocorticoids in the prevention of hyaline membrane disease].
    Leroy JL
    J Gynecol Obstet Biol Reprod (Paris); 1982; 11(1):152-7. PubMed ID: 6896522
    [No Abstract]   [Full Text] [Related]  

  • 55. Steroids in perinatology.
    Narayan S; Deorari AK
    Indian Pediatr; 2002 Apr; 39(4):347-61. PubMed ID: 11976464
    [No Abstract]   [Full Text] [Related]  

  • 56. [Effect of antenatal corticosteroids therapy on the mortality and morbidity of small for gestational age infants born at 24-34 completed weeks: a retrospective multicenter study].
    Collaborative Study Group for Respiratory Distress Syndrome in Preterm Infants
    Zhonghua Er Ke Za Zhi; 2017 Aug; 55(8):613-618. PubMed ID: 28822438
    [No Abstract]   [Full Text] [Related]  

  • 57. [Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study].
    Fekih M; Chaieb A; Sboui H; Denguezli W; Hidar S; Khairi H
    Tunis Med; 2002 May; 80(5):260-5. PubMed ID: 12534029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The role of corticosteroids in the lungs' maturation in expected premature birth].
    Fatusić Z
    Med Arh; 2004; 58(4):249-52. PubMed ID: 15526598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prevention of hyaline membrane disease: new concepts and approaches to therapy.
    Farrell PM; Kotas RV
    Adv Pediatr; 1976; 23():213-69. PubMed ID: 795280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Perinatal corticotherapy: updates].
    Hamon I; Hascoet JM
    J Gynecol Obstet Biol Reprod (Paris); 2001 Oct; 30(6 Suppl):S50-3. PubMed ID: 11883016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.